RMG 02
Alternative Names: RMG-02Latest Information Update: 26 May 2023
At a glance
- Originator ROMEG Therapeutics
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cardiovascular disorders
Most Recent Events
- 18 Apr 2023 RMG 02 is available for licensing as of 18 Apr 2023. https://romegrx.com/investors/
- 18 Apr 2023 Phase-II clinical trials in Cardiovascular disorders, prior April 2023 (unspecified route) (Romeg pipeline, April 2023)
- 18 Apr 2023 RMG 02 receives Orphan Drug status for Cardiovascular disorders, before April 2023 (Romeg pipeline, April 2023)